Dr. Blumenschein on Immunotherapy Combinations in NSCLC

George R. Blumenschein, MD
Published: Friday, Nov 03, 2017



George R. Blumenschein, MD, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combinations with immunotherapy for patients with non-small cell lung cancer (NSCLC).

Immunotherapy is being combined in numerous different ways, either with other immunotherapy regimens or with chemotherapy, explains Blumenschein.

Combinations are being investigated in clinical trials for patients who are not candidates for single-agent immunotherapy. There will be a shift to use more immunotherapy in the frontline setting, states Blumenschein.
 
SELECTED
LANGUAGE


George R. Blumenschein, MD, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combinations with immunotherapy for patients with non-small cell lung cancer (NSCLC).

Immunotherapy is being combined in numerous different ways, either with other immunotherapy regimens or with chemotherapy, explains Blumenschein.

Combinations are being investigated in clinical trials for patients who are not candidates for single-agent immunotherapy. There will be a shift to use more immunotherapy in the frontline setting, states Blumenschein.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x